Plain-English translation of NCT06968845 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing an experimental medication called that you would inhale using a special inhaler device. The medication is designed to protect your lung cells and reduce lung scarring in people with idiopathic pulmonary fibrosis (IPF), a serious condition where lung tissue becomes progressively scarred and damaged. This trial will measure whether the treatment is safe and whether it improves your lung function and symptoms.
Idiopathic pulmonary fibrosis is a progressive disease where lung tissue becomes increasingly scarred, making it harder to breathe and reducing oxygen uptake over time. Current treatments slow the disease in some patients, but researchers believe this medication may work differently by both protecting lung cells and controlling the scarring process itself.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic up to 9 times over about 28 weeks. At each visit, you'll have your lung function tested, blood work done, heart rhythm checked, and vital signs measured. You'll take the study medication (or placebo) twice daily using an inhaler at home, and report any side effects or changes in how you feel between visits. Half of participants will receive the active medication and half will receive placebo, with neither you nor the researchers knowing which you're taking until the trial ends.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States